64
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Drug repurposing and combination therapy for glioblastoma treatment

      Published
      conference-abstract
      1 , 2 , 3 , 3 , 4 , 2
      ScienceOpen
      International Drug Repurposing Conference 2025 (iDR25)
      7-8 May 2025
      Drug repurposing, combination therapy, glioblastoma

            Abstract

            Introduction

            Glioblastoma (GBM) remains one of the most aggressive brain cancers, with standard treatment unchanged since 2005. Challenges like the blood-brain barrier, tumor invasiveness, and resistance to standard therapies have hindered the discovery of new treatment options. However, personalized drug repurposing (PDR) and combination drug therapy (CDT) may offer promising solutions. PDR repurposes existing medicines, leveraging known efficacy for faster, cost-effective treatment discovery for GBM in a patient-tailored manner. However, treatment resistance to monotherapy in GBM is prevalent due to its genetic and phenotypic heterogeneity. To combat this, CDT targets multiple pathways simultaneously, improving treatment efficacy and patient outcomes.

            Methods

            We developed SPARC (Synergistic Prediction for Anticancer Repurposing and Combination), a tool integrating PDR and CDT to identify personalized drug combinations. SPARC leverages patient-derived GBM tissues and drug screening data. It incorporates two models: (i) Mechanisms of Action Landscape (MOAL), prioritizing drug pairings based on mechanisms of action, and (ii) Augmented Cancer Drug Atlas (ACDA), a machine learning model predicting drug synergy using the ALMANAC dataset of 100+ FDA-approved drugs.

            Results

            Using leave-one-out cross-validation, SPARC correctly predicted synergy in 60% of synergistic drug pairs and 65% of non-synergistic drug pairs. These findings suggest that SPARC can serve as a valuable tool for prioritizing drug combinations for experimental validation, ultimately contributing to more efficient drug discovery and personalized treatment strategies.

            Conclusion

            The SPARC model is a promising tool to identify personalized drug combinations for glioblastoma. Currently, in silico predicted synergistic drug combinations are being validated on patient-derived GBM cell cultures. SPARC will be extended to include advanced deep learning and predictive models to enhance the functionality.

            Author and article information

            Conference
            ScienceOpen
            12 April 2025
            Affiliations
            [1 ] Erasmus MC ( https://ror.org/018906e22)
            [2 ] Department of Neurosurgery, Erasmus MC Rotterdam, Netherlands ( https://ror.org/057w15z03)
            [3 ] Department of Neurosurgery, Erasmus MC Rotterdam, Netherlands ( https://ror.org/057w15z03)
            [4 ] Pathology & Clinical Bioinformatics, Erasmus MC Rotterdam, Netherlands ( https://ror.org/057w15z03)
            Author information
            https://orcid.org/0000-0001-9285-991X
            Article
            10.14293/iDR.25.012MK
            d846c4a7-af41-41bc-93f3-de4cab991af0

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            International Drug Repurposing Conference 2025
            iDR25
            2
            Amsterdam, The Netherlands
            7-8 May 2025
            History
            Product

            ScienceOpen


            Drug repurposing,combination therapy,glioblastoma

            Comments

            Comment on this article